Click Therapeutics announced today that it acquired the assets of Better Therapeutics to accelerate its digital therapeutic development initiatives.
Better Therapeutics’ assets include digital therapeutics for obesity and cardiometabolic disease. The company offered the AspyreRx (BT-001) FDA-authorized prescription digital therapeutic (PDT) for type 2 diabetes. Its assets also include BT-004, a liver disease therapeutic that received FDA breakthrough device designation in February. Better Therapeutics also developed BT-002 for reducing blood pressure in those with hypertension and BT-003 for reducing cholesterol.
Despite those positive developments, Better Therapeutics ceased operations in March, terminating its employees after a special board meeting. It faced a similar fate to fellow digital therapeutic maker Pear Therapeutics, which scaled down operations after filing bankruptcy last year.
Click Therapeutics, meanwhile, develops digital treatments for psychiatry, central nervous system and pain disorders. It also has a candidate for obesity but now expects to add the established Better Therapeutics offerings to its portfolio. The company anticipates accelerated development timelines and a best-in-class digital therapy for chronic weight management.
The company wants the resulting digital therapeutic to work with anti-obesity and diabetes medications like GLP-1s.
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, chief commercial officer of Click Therapeutics. “The current one-size-fits-all approach to obesity management can be improved with innovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportunity to create data-driven contracting models with payers. By collaborating with pharma, payers, providers and patients to layer these capabilities onto the latest drugs, we can transform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”
